6 ago 2018 ano - FDA issued the draft guidance for industry, “Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment,” which is intended to assist sponsors in developing drugs for medication-assisted treatment of opioid use disorder (OUD) and addresses the clinical endpoints acceptable to demonstrate effectiveness of such drugs.

Adicionado na linha do tempo:

Opioids and the FDA

ByAnastasia

13 nov 2018

0 0 330

Data: